Safeguarding Women from Chemical Abortion Act
Summary
S.4066 is early-stage legislation targeting mifepristone. No direct market impact identified. Direct public company exposure is minimal, limited to one CDMO with a small contract, and no market-moving impact is expected at this procedural stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bill is in earliest procedural stage with no hearings or markup
- 2.No funding authorized; no direct financial impact on any sector
- 3.No specific public companies identified as materially affected
Market Implications
No market implications at this stage. The bill does not authorize spending, name any public company, or create a financial mechanism that would affect sectors or tickers. Investors should monitor this bill only for progression beyond committee referral, which is unlikely in the near term.
Full Analysis
S.4066, the Safeguarding Women from Chemical Abortion Act, was introduced in the Senate on March 11, 2026, and referred to the Committee on Health, Education, Labor, and Pensions. The bill seeks to withdraw FDA approval of mifepristone for pregnancy termination and establish a federal tort for harm caused by chemical abortion drugs. It is in the earliest legislative stage with only two actions taken. No funding is authorized or appropriated. A companion bill (HR7902) exists in the House but also remains in early committee referral. No specific public companies are directly named or materially impacted by this bill. The single CDMO with a small mifepristone contract is not identified in available data, and the contract value is immaterial to any public company's revenue. No real market data was provided to analyze price trends. The bill faces a long legislative path with low probability of near-term passage, as it must clear committee, pass both chambers, and be signed into law.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SAVE Moms and Babies Act of 2026
To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
Chemical Abortion Risk Awareness Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →